undamentalytics Newsletter

Capricor Therapeutics, Inc. valuation and forecast

Explore the models for Capricor Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

10 analysts, Oct 2026
Buy440%
Hold660%
Sell00%

Monthly trend

  1. Oct 202613610
  2. Sep 202613610
  3. Aug 2026279
  4. Jul 20261010

Counts of recommendations published by analysts covering Capricor Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

CAPR valuation questions

How does Fundamentalytics value Capricor Therapeutics, Inc.?
We use the models that fit Capricor Therapeutics, Inc.'s business and available financial data: forward price-to-sales vs peers. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Capricor Therapeutics, Inc.

Compare with peers